Cargando…
Next-generation of selective histone deacetylase inhibitors
Histone deacetylases (HDACs) are clinically validated epigenetic drug targets for cancer treatment. HDACs inhibitors (HDACis) have been successfully applied against a series of cancers. First-generation inhibitors are mainly pan-HDACis that target multiple isoforms which might lead to serious side e...
Autores principales: | Yang, Feifei, Zhao, Na, Ge, Di, Chen, Yihua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Royal Society of Chemistry
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065321/ https://www.ncbi.nlm.nih.gov/pubmed/35519364 http://dx.doi.org/10.1039/c9ra02985k |
Ejemplares similares
-
Development of Coumarin-Based Hydroxamates as Histone Deacetylase Inhibitors with Antitumor Activities
por: Zhao, Na, et al.
Publicado: (2020) -
Kinetically selective inhibitors of histone deacetylase 2 (HDAC2) as cognition enhancers
por: Wagner, F. F., et al.
Publicado: (2015) -
Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020) -
Antitumor Action of a Novel Histone Deacetylase Inhibitor, YF479, in Breast Cancer()
por: Zhang, Tao, et al.
Publicado: (2014) -
Borinostats: solid-phase synthesis of carborane-capped histone deacetylase inhibitors with a tailor-made selectivity profile
por: Selg, Christoph, et al.
Publicado: (2021)